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Pneumonia is now widely regarded as the dominant
cause of child mortality in the developing world
with over 150 million cases and almost 2.4 million
deaths annually(1). Although there are remarkable
advances in preventive strategies including nutrition
interventions such as promotion of exclusive breast-
feeding, environmental control such as reduction of
indoor air pollution and newer effective vaccines(2),
antibiotic therapy remains the mainstay of manage-
ment and treatment strategies(3).
In this issue of Indian Pediatrics, Zhang, et al.(4)
from the University of Rio Grande (Brazil) present
their evaluation of empiric antibiotic therapy based
on a retrospective evaluation of data from a
cohort of children (29 d - 12 yr of age) admitted with
community acquired pneumonia between 1991-
2001.  Notwithstanding the relatively higher rates of
treatment failure observed from 1999-2001, the
overall treatment success rates were close to 95%,
suggesting that their strategy of empiric therapy
worked. However, these findings are difficult to
interpret and extrapolate to community settings, as
population denominators and cause specific
mortality rates are not provided. Only 4% of cases
with either pleural effusion or more severe disease
had cultures obtained and the relatively high rates of
positive cultures (61%) in this group do suggest that
these represented a subgroup of relatively severe
disease. The choice of antibiotics and reasons for
therapeutic changes are also unclearly defined,
indicating that a variety of management protocols, if
any, were in place over this time. It is therefore
unclear if the empiric therapy protocols were
influenced by adequate knowledge of the back-
ground rates of antimicrobial resistance, other case
management strategies or therapeutic recommenda-
tions in Rio Grande over this period of time. As
indicated by Graham, et al.(5), the greatest potential
for reducing pneumonia-related deaths in health
facilities is wider implementation of the current
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guidelines built around a few core activities such as
training of healthcare providers, appropriate
antibiotics and availability of oxygen.
Given the difficulties in obtaining appropriate
microbiological information in a timely manner
among children with community-acquired pneu-
monia, it is imperative that the choice of empirical
antibiotics is based on sound knowledge of common
bacterial pathogens and sensitivities in the region.
There is strong evidence of emerging resistance
among common organisms causing pneumonia from
a variety of community settings(6,7), and these
should inform policy for the choice of empirical
therapy. In areas with special problems such as
resistance of common respiratory bacterial
pathogens such as Streptoccoccus pneumoniae and
Hemophilus influenzae to first line antibiotics(8) and
emergence of methicillin-resistant Staphylococcus
infections(9) in community settings, antibiotic
choices must be based on available local data.
This approach does require adequate availability
of surveillance information as well as systematic
collection of local and regional microbiological
information. The fact that our current clinical criteria
for the diagnosis of pneumonia may also include a
substantial proportion with non-bacterial lower
respiratory infections, criteria for recognizing and
instituting empirical antibiotic therapy must be
developed carefully and periodically reviewed.
However, once developed, such evidence-based
protocols for the recognition and treatment of
childhood pneumonia must be implemented at scale
in close coordination between community-based
outreach services as well as referral facilities. Data
and facility-based case series such as the one
reported by Zhang, et al.(4) are an extremely
important step in this direction and must be coupled
with triangulation from additional health system
information including periodic microbiological
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surveillance. This must lead to a careful strategy of
avoiding large scale carte blanche administration of
antibiotics on empirical grounds while ensuring that
there is no inordinate delay in instituting appropriate
treatment. This balancing of "access and excess" is
key in ensuring that we save lives today and also
avoid the specter of multi-drug resistant infections
tomorrow(10).
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